ST
Sutro Biopharma, Inc.
STRO · NASDAQ
$19.10 -0.57% (-$0.11)
1M -25.19%
Market Cap $184.8M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$27.27
42.8% upside
Current Price
$19.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, STRO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
45 /100
Fair P/S 4.04x
P/E N/A
EV/EBITDA N/A
Growth
87 /100
Growing Rev. growth 14.78%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 97.20%
Net margin 395.25%
Op. margin 309.87%
Quality
4 /100
Poor ROIC 95.49%
ROA 92.89%
Asset turnover 0.24x
Debt
43 /100
Moderate Current ratio 3.32x
Int. coverage -3.51x
Debt/Equity N/A
Stability
20 /100
Unstable Beta 1.49x
Rev. volatility 95.01%
EPS volatility 52.21%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about STRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jane Chung
Employees
128
Headquarters
South San Francisco
Upcoming events
05 NOV
Earnings
Upcoming earnings report